A Phase 1 Study of REGN6569, an Anti-GITR mAb, with Cemiplimab in Patients with Advanced Solid Tumor Malignancies.
Phone: (800) 411-7999
A Phase 1 Study of REGN6569, an Anti-GITR mAb, with Cemiplimab in Patients with Advanced Solid Tumor Malignancies.